Extend Biosciences Inc. Their goal is to improve the pharmacokinetic properties of peptides and proteins, which have traditionally been challenging to bring to market due to their removal from circulation before administering therapeutic value. With their proprietary D-VITylation® platform technology, Extend Biosciences significantly enhances the circulating half-life and bioavailability of peptides and proteins.

This breakthrough enables the development of potent and specific drugs that have a sustained delivery, transforming promising peptides into long-acting therapeutics. Extend Biosciences focuses on addressing critical medical needs, such as cancer cachexia and hypoparathyroidism. Cachexia, a metabolic syndrome characterized by involuntary weight loss and muscle wasting, affects more than half of all cancer patients and is responsible for over 20% of cancer-related deaths.

Hypoparathyroidism, a rare disorder, causes low levels of calcium in the blood due to insufficient parathyroid hormone levels. With their innovative D-VITylation® technology, Extend Biosciences aims to revolutionize the treatment of these conditions and improve patient outcomes